Merck priority review for Pulmonary Arterial Hypertension candidate

 Application based on clinically meaningful results from the Phase 3 STELLAR trial

If approved, sotatercept would be the first in its class, bringing a novel approach to address a rare and progressive disease of the pulmonary arteries

https://www.businesswire.com/news/home/20230928840253/en/